Systemic factors drive ADHD diagnosis surge as GPs expand prescribing roles
Original framing: “How to safeguard against overdiagnosis when more GPs treat ADHD” — The Conversation - Global
The original framing omits the role of Indigenous and non-Western approaches to neurodiversity, the historical context of ADHD as a diagnostic construct, and the perspectives of neurodiverse communities. It also fails to address socioeconomic disparities in diagnosis rates and the potential for alternative therapies such as lifestyle, education, and community-based interventions.
Medium structural omission detected in mainstream coverage.
This narrative is produced by academic and medical institutions, often in collaboration with pharmaceutical stakeholders, for a public seeking medical solutions to complex behavioral issues. The framing serves to normalize increased prescription rates while obscuring the influence of Big Pharma and the lack of systemic alternatives. It obscures the power dynamics between pharmaceutical companies, healthcare providers, and patients, which shape diagnostic and treatment pathways.
ADHD has evolved from a narrow concept of hyperactivity in the 1960s to a broad diagnostic category today, influenced by shifting cultural norms and pharmaceutical interests. Historical parallels include the medicalization of other conditions, such as autism and depression, where diagnostic expansion has often followed increased pharmaceutical marketing.
The surge in ADHD prescriptions is not merely a medical issue but a systemic one, shaped by pharmaceutical influence, diagnostic inflation, and a lack of culturally responsive care.